(Corrects spelling of Remdesivir in headline)
WASHINGTON, May 1 (Reuters) - The chief executive of Gilead Sciences Inc, maker of the experimental coronavirus drug Remdesivir, said on Friday he expected the Food and Drug Administration to act quickly over the company's application for approval.
It would try to get the drug to as many people as possible if it was approved, he said.
"We're moving very quickly with the FDA," Daniel O'Day said in an interview with NBC's Today show. "And I expect that they're going to act very quickly." (Reporting by Doina Chiacu; editing by John Stonestreet)